Clinical trials
Recurrence trials in India
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
56 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 4 |
| 2008 | 4 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 2 |
| 2013 | 2 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 6 |
| 2024 | 8 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 24 |
| Recruiting | 9 |
| Active, not recruiting | 9 |
| Unknown status | 8 |
| Terminated | 3 |
| Withdrawn | 2 |
| Temporarily not available | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 8 |
| Postgraduate Institute of Dental Sciences Rohtak | 6 |
| Biogen | 5 |
| Pfizer | 4 |
| Tata Memorial Hospital | 3 |
| All India Institute of Medical Sciences | 2 |
| AstraZeneca | 2 |
| Aurigene Discovery Technologies Limited | 2 |
| Celgene | 2 |
| GSVM Medical College | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Recurrence | 56 |
| Multiple Sclerosis | 7 |
| Multiple Myeloma | 6 |
| Breast Neoplasms | 5 |
| Neoplasms | 5 |
| Uterine Cervical Neoplasms | 5 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 |
| Hernia, Inguinal | 3 |
| Multiple Sclerosis, Relapsing-Remitting | 3 |
| Neoplasm Metastasis | 3 |
Trials
Showing 26 to 50 of 56. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.